Lawsuit filed for Investors who lost money with shares of Geron Corporation (NASDAQ: GERN)

An investor, who purchased shares of Geron Corporation (NASDAQ: GERN), filed a lawsuit over alleged violations of Federal Securities Laws by Geron Corporation in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and for certain investors are short and strict deadlines running. Deadline: May 12, 2025. NASDAQ: GERN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Foster City, CA based Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.

On February 26, 2025, Geron Corporation (NASDAQ: GERN) announced its financial results for the fourth quarter of fiscal year 2024, disclosing that Rytelo's growth had flattened over the preceding months, attributing the diminished growth on seasonality, competition, lack of awareness for Rytelo, and the burden of the monitoring requirement necessary for the drug treatment.

Shares of Geron Corporation (NASDAQ: GERN) declined from $5.34 per share on June 12, 2024, to $1.65 per share on March 11, 2025.

The plaintiff claims that between June 7, 2024 and February 25, 2025, the defendants provided investors with material information concerning defendants' expectations for the launch and growth potential of Rytelo (imetelstat), and that the defendants' statements included, among other things, confidence in Geron's ability to capitalize on the purportedly significant unmet need for the drug and to execute on its commercial plan to target first-line ESA ineligible patients, while continually minimizing the risks associated with the burden of the weekly monitoring requirement for Rytelo and the impacts of seasonality and existing competition on the drug's sales.

Those who purchased shares of Geron Corporation (NASDAQ: GERN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.